AITIA INTERNATIONAL
Aitia has three main divisions that are intelligent applications and web services, telecommunications, and speech technology. They have flexible solutions for emerging industrial problems, from real-time asset monitoring to the integration of small IoT devices in high volume. All their advanced solutions are available for all generations of cellular networks (GSM, GPRS, 3G, LTE, and 5G) as well as for IP-based data networks.
AITIA INTERNATIONAL
Industry:
Speech Recognition Telecommunications Web Apps
Founded:
1995-01-01
Address:
Budapest, Budapest, Hungary
Country:
Hungary
Website Url:
http://www.aitia.ai
Total Employee:
11+
Status:
Active
Contact:
+36 1 4538080
Email Addresses:
[email protected]
Similar Organizations
AITR
AITR specializes in the development of control systems, telecommunications and renewable energy.
ECOPROYING
ECOPROYING offers installations and maintenance services of telecommunications infrastructures.
MDDSL
MDDSL is an internet solutions company that provides modern communication and telecommunications technology.
Virtual Talks
Virtual Talks is an interactive solution company that offers web services, telecommunications, mobile technology, and billing solutions.
Current Employees Featured
Founder
Official Site Inspections
http://www.aitia.ai
- Host name: 37-220-137-26.static.acetelecom.hu
- IP address: 37.220.137.26
- Location: Vác Hungary
- Latitude: 47.7759
- Longitude: 19.1361
- Timezone: Europe/Budapest
- Postal: 2600
More informations about "Aitia International"
Leading Experts in AI-Enabled Drug Discovery - Aitia Bio
At Aitia, derived from the Greek word for causality, we are rapidly turning aspiration into reality through the convergence of multi-omic patient data, high-performance computing, and causal …See details»
Aitia Enters into Multi-Year AI-Driven Drug Discovery and Drug ...
May 17, 2023 Aitia is the leader in the development and application of Causal AI and Digital Twins to discover the next generation of breakthrough drugs in neurodegenerative disorders, …See details»
Aitia - The Org
Aitia is the leader in the application of Causal AI and Digital Twins to discover the next generation of breakthrough drugs. By leveraging the convergence of multi-omic patient data, high …See details»
Aitia - LinkedIn
Aitia | 5,969 followers on LinkedIn. Leader in the application of Causal AI and Digital Twins to discover the next generation of breakthrough drugs | Aitia is the leader in the development and ...See details»
Orion and Aitia enter AI-Driven Drug Discovery and Drug …
Sep 25, 2024 About Aitia Aitia is an AI-enabled biotechnology company deploying causal AI and creating Gemini Digital Twins to discover the next generation of breakthrough drugs in …See details»
Aitia - Crunchbase Company Profile & Funding
Aitia is the leader in the application of Causal AI and Digital Twins to discover the next generation of breakthrough drugs. By leveraging the convergence of multi-omic patient data, high …See details»
Discovering Next Generation Drugs with Gemini Digital …
Our mission is to build the leading AI-enabled biotech company, to reveal hidden biological mechanisms of disease and discover breakthrough drugs.By harnessing the power of causal AI, human multi-omics data, and our Gemini …See details»
Orion and Aitia Enter AI-Driven Drug Discovery and Drug …
Sep 25, 2024 Orion Corporation and Aitia, an AI-enabled biotechnology company and the leader in the development and application of Causal AI and "Digital Twins" to discover and develop …See details»
Causal artificial intelligence and digital twins are
Aitia previously operated as a provider of AI technology. Over the past two years, the company has evolved and become an AI-powered drug discovery and development organization.See details»
Orion and Aitia enter AI-Driven Drug Discovery and Drug …
Sep 25, 2024 Orion Corporation and Aitia, an AI-enabled biotechnology company and the leader in the development and application of Causal AI and "Digital Twins" to discover and develop …See details»
Aitia Enters into Multi-Year AI-Driven Drug Discovery and Drug ...
May 17, 2023 Aitia is the leader in the development and application of Causal AI and Digital Twins to discover the next generation of breakthrough drugs in neurodegenerative disorders, …See details»
Aitia Expand Collaboration with Servier to Discover and Develop …
Oct 30, 2024 Aitia, a biotech company pioneering the use of causal AI and Digital Twins in drug discovery and development, is expanding its collaboration with Servier, a global and …See details»
Orion and Aitia Enter AI-Driven Drug Discovery and Drug …
Sep 25, 2024 Aitia to receive payments totalling to more than $10 million per target plus royalties. Somerville, MA, USA and Espoo, Finland, September 25, 2024 – Orion Corporation …See details»
Aitia Company Profile 2024: Valuation, Funding & Investors
Developer of an artificial intelligence-based digital twins technology designed to revolutionize drug discovery and development. The company's technology uses machine learning to create …See details»
Orion and Aitia enter AI-Driven Drug Discovery and Drug
Sep 25, 2024 Aitia is an AI-enabled biotechnology company deploying causal AI and creating Gemini Digital Twins to discover the next generation of breakthrough drugs in …See details»
Aitia Company Profile - Office Locations, Competitors, Revenue
Aitia has 5 employees at their 1 location and $76.06 m in total funding,. See insights on Aitia including office locations, competitors, revenue, financials, executives, subsidiaries and more …See details»
Aitia and Pancreatic Cancer Action Network Partner to Transform …
Sep 27, 2023 LOS ANGELES and SOMERVILLE, MA, Sept 27, 2023: Aitia, the leader in the development and application of Causal AI and Digital Twins to discover and develop new …See details»
What is AIaaS? (AI as a Service) | Microsoft Azure
Artificial intelligence as a service is a cloud-based model that provides access to AI tools and capabilities on a subscription basis. It allows users to reap the benefits of artificial intelligence …See details»
Charles River and Aitia Enter Strategic Agreement to Utilize Logica …
Nov 13, 2023 Strategic partnership includes co-development of patient-derived xenograft (PDX) Digital Twins for in vivo oncology research Charles River to make an equity investment in Aitia …See details»